SG10201401515YA - PCSK9 vaccine - Google Patents
PCSK9 vaccineInfo
- Publication number
- SG10201401515YA SG10201401515YA SG10201401515YA SG10201401515YA SG10201401515YA SG 10201401515Y A SG10201401515Y A SG 10201401515YA SG 10201401515Y A SG10201401515Y A SG 10201401515YA SG 10201401515Y A SG10201401515Y A SG 10201401515YA SG 10201401515Y A SG10201401515Y A SG 10201401515YA
- Authority
- SG
- Singapore
- Prior art keywords
- pcsk9 vaccine
- pcsk9
- vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/005—Trypanosoma antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Mycology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23954109P | 2009-09-03 | 2009-09-03 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201401515YA true SG10201401515YA (en) | 2014-08-28 |
Family
ID=43413463
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201401515YA SG10201401515YA (en) | 2009-09-03 | 2010-08-23 | PCSK9 vaccine |
SG10201401516XA SG10201401516XA (en) | 2009-09-03 | 2010-08-23 | Pcsk9 vaccine |
SG2012010740A SG178447A1 (en) | 2009-09-03 | 2010-08-23 | Pcsk9 vaccine |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201401516XA SG10201401516XA (en) | 2009-09-03 | 2010-08-23 | Pcsk9 vaccine |
SG2012010740A SG178447A1 (en) | 2009-09-03 | 2010-08-23 | Pcsk9 vaccine |
Country Status (30)
Country | Link |
---|---|
US (4) | US8889144B2 (en) |
EP (3) | EP2865752A1 (en) |
JP (5) | JP2013503623A (en) |
KR (3) | KR101660578B1 (en) |
CN (3) | CN104548089B (en) |
AR (2) | AR078247A1 (en) |
AU (1) | AU2010290931B2 (en) |
BR (1) | BR112012004807A2 (en) |
CA (2) | CA2771770A1 (en) |
CO (1) | CO6501190A2 (en) |
DK (1) | DK2473605T3 (en) |
ES (1) | ES2670576T3 (en) |
HK (3) | HK1174056A1 (en) |
HU (1) | HUE037416T2 (en) |
IL (2) | IL218229A (en) |
MX (1) | MX2012002639A (en) |
MY (1) | MY163512A (en) |
NO (1) | NO2473605T3 (en) |
NZ (3) | NZ620441A (en) |
PE (3) | PE20161560A1 (en) |
PH (2) | PH12016500004A1 (en) |
PL (1) | PL2473605T3 (en) |
PT (1) | PT2473605T (en) |
RU (2) | RU2538162C2 (en) |
SA (3) | SA110310687B1 (en) |
SG (3) | SG10201401515YA (en) |
SI (1) | SI2473605T1 (en) |
TR (1) | TR201808222T4 (en) |
TW (1) | TWI400085B (en) |
WO (1) | WO2011027257A2 (en) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107266582B (en) | 2008-08-29 | 2021-09-10 | 口腔健康澳洲私人有限公司 | Prevention, treatment and diagnosis of Porphyromonas gingivalis infection |
US8552165B2 (en) * | 2008-12-09 | 2013-10-08 | Heather Davis | Immunostimulatory oligonucleotides |
PE20110998A1 (en) | 2008-12-09 | 2012-02-10 | Coley Pharm Group Inc | IMMUNOSTIMULATORY OLIGONUCLEOTIDES |
GB201005005D0 (en) * | 2010-03-25 | 2010-05-12 | Angeletti P Ist Richerche Bio | New vaccine |
US20140004142A1 (en) * | 2011-03-02 | 2014-01-02 | Pfizer Inc. | Pcsk9 vaccine |
EP2532359A1 (en) | 2011-06-10 | 2012-12-12 | Affiris AG | CETP fragments |
EP2570135B1 (en) | 2011-09-13 | 2016-01-27 | Affiris AG | PCSK9 Vaccine |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
EP2703483A1 (en) | 2012-08-29 | 2014-03-05 | Affiris AG | PCSK9 peptide vaccine |
EP2908854A2 (en) * | 2012-10-17 | 2015-08-26 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
US10058630B2 (en) * | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
WO2014074509A1 (en) * | 2012-11-07 | 2014-05-15 | Vacplanta Limted | Production of an immunogen using a plant virus |
US10117923B2 (en) | 2012-11-07 | 2018-11-06 | Vacplanta Limited | Production of an immunogen using a plant virus |
TWI641382B (en) * | 2013-01-31 | 2018-11-21 | 韓美藥品股份有限公司 | A method of virus inactivation in composition comprising factor vii |
CN104043120B (en) * | 2013-03-13 | 2017-05-31 | 南京赛威信生物医药有限公司 | Hepatitis b vaccine |
WO2015123291A1 (en) | 2014-02-11 | 2015-08-20 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Pcsk9 vaccine and methods of using the same |
US10004791B2 (en) * | 2014-02-28 | 2018-06-26 | Affiris Ag | Peptide vaccines against PCSK9 |
CN104558199B (en) * | 2014-09-05 | 2018-07-06 | 成都康弘生物科技有限公司 | A kind of fusion protein preparation for treating hypercholesterolemia and application thereof |
RU2736642C2 (en) * | 2015-07-20 | 2020-11-19 | Зоэтис Сервисиз Ллс | Liposomal adjuvant compositions |
EP3365006A1 (en) | 2015-10-19 | 2018-08-29 | Cadila Healthcare Limited | New adjuvant and vaccine composition containing the same |
WO2017076873A1 (en) * | 2015-11-03 | 2017-05-11 | Affiris Ag | Method for vaccination against a self-antigen in a human patient |
US10980876B2 (en) * | 2016-03-25 | 2021-04-20 | Osaka University | Conjugate vaccine targeting a disease-causing biological protein |
CA3026823A1 (en) * | 2016-06-24 | 2017-12-28 | F. Hoffmann-La Roche Ag | Compositions and methods for treating cardiovascular disease |
CN106822881A (en) * | 2016-12-09 | 2017-06-13 | 四川大学 | A kind of hyperlipoproteinemia vaccine for PCSK9 |
CA3058567A1 (en) * | 2017-04-13 | 2018-10-18 | Cadila Healthcare Limited | Novel peptide based pcsk9 vaccine |
CN107488215A (en) * | 2017-07-19 | 2017-12-19 | 邱志华 | The immunogenicity peptide fragment of people's proprotein convertases subtilisin 9 and its carrier bacterin |
US20220380425A1 (en) * | 2019-07-04 | 2022-12-01 | Cadila Healthcare Limited | Angptl3 based vaccine for the treatment of liver disease |
WO2021154947A1 (en) * | 2020-01-28 | 2021-08-05 | Ubi Ip Holdings | Peptide immunogens targeting pcsk9 and formulations thereof for prevention and treatment of pcsk9-mediated disorders |
WO2021176434A1 (en) | 2020-03-01 | 2021-09-10 | Valneva Austria Gmbh | Cpg-adjuvanted sars-cov-2 virus vaccine |
WO2022147373A1 (en) * | 2020-12-31 | 2022-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins |
WO2023161526A1 (en) | 2022-02-28 | 2023-08-31 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN |
CN117327159A (en) * | 2023-07-31 | 2024-01-02 | 杭州纽龙生物科技有限公司 | Alkali-resistant mutation method for protein A |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773946A (en) | 1969-09-02 | 1973-11-20 | Parke Davis & Co | Triglyceride-lowering compositions and methods |
US3930024A (en) | 1969-09-02 | 1975-12-30 | Parke Davis & Co | Pharmaceutical compositions and methods |
JPS5522636A (en) | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
WO1980000727A1 (en) | 1978-09-29 | 1980-04-17 | Secretary Energy Brit | Improvements in and relating to electrical power transmission in fluid wells |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
AU548727B2 (en) | 1981-03-12 | 1986-01-02 | Gruppo Lepetit S.P.A. | Beta-lactam acetic acid derivatives |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
DE3280400D1 (en) | 1981-10-23 | 1992-06-04 | Molecular Biosystems Inc | OLIGONUCLEOTIDES MEDICINE AND THEIR PRODUCTION METHOD. |
IL64542A0 (en) | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
JPS60136512A (en) | 1983-12-26 | 1985-07-20 | Eisai Co Ltd | Remedy and preventive for hyperlipemia |
DE3423166A1 (en) | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | ALPHA, OMEGA DICARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS |
US4722840A (en) | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
US4709017A (en) | 1985-06-07 | 1987-11-24 | President And Fellows Of Harvard College | Modified toxic vaccines |
US5374426A (en) | 1986-09-03 | 1994-12-20 | University Of Saskatchewan | Rotavirus nucleocapsid protein VP6 in vaccine compositions |
US4950740A (en) | 1987-03-17 | 1990-08-21 | Cetus Corporation | Recombinant diphtheria vaccines |
GB8815795D0 (en) | 1988-07-02 | 1988-08-10 | Bkl Extrusions Ltd | Glazing bead |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
DE3841091A1 (en) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE |
ES2055785T3 (en) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | SYNTHETIC PEPTIDES AND THEIR USE AS UNIVERSAL VEHICLES FOR THE PREPARATION OF IMMUNOGENOUS CONJUGATES SUITABLE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES. |
HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
JPH04506662A (en) | 1989-07-14 | 1992-11-19 | アメリカン・サイアナミド・カンパニー | Cytokinin and hormone carriers for conjugate vaccines |
NZ235315A (en) | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
IT1237764B (en) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES. |
SE466259B (en) | 1990-05-31 | 1992-01-20 | Arne Forsgren | PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE |
JP2999579B2 (en) | 1990-07-18 | 2000-01-17 | 武田薬品工業株式会社 | DNA and its uses |
EP0471177B1 (en) | 1990-08-13 | 1995-10-04 | American Cyanamid Company | Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines |
WO1992011291A1 (en) | 1990-12-20 | 1992-07-09 | Smithkline Beecham Biologicals (S.A.) | Vaccines based on hepatitis b surface antigen |
DE4202394A1 (en) | 1991-04-04 | 1992-10-08 | Teves Gmbh Alfred | SWIMMING CALIPER PART COVER DISC BRAKE WITH A BRAKE CASE MADE OF LIGHT METAL |
IT1262896B (en) | 1992-03-06 | 1996-07-22 | CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES. | |
CA2135052A1 (en) | 1992-05-06 | 1993-11-11 | R. John Collier | Diphtheria toxin receptor-binding region |
ES2143716T3 (en) | 1992-06-25 | 2000-05-16 | Smithkline Beecham Biolog | VACCINE COMPOSITION CONTAINING ADJUVANTS. |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
SG48309A1 (en) | 1993-03-23 | 1998-04-17 | Smithkline Beecham Biolog | Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
EP1167377B2 (en) | 1994-07-15 | 2012-08-08 | University of Iowa Research Foundation | Immunomodulatory oligonucleotides |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
CN1185811A (en) | 1995-03-31 | 1998-06-24 | H·沃尔夫 | Antigen presentation system on retrovirus-like particles |
GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
ES2241042T3 (en) | 1996-10-11 | 2005-10-16 | The Regents Of The University Of California | IMMUNO STIMULATOR POLINUCLEOTIDE CONJUGATES / IMMUNOMODULATOR MOLECULA. |
IL119971A (en) | 1997-01-07 | 2003-02-12 | Yissum Res Dev Co | Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids |
AUPO517897A0 (en) | 1997-02-19 | 1997-04-11 | Csl Limited | Chelating immunostimulating complexes |
CA2281838A1 (en) | 1997-02-28 | 1998-09-03 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders |
AU753688B2 (en) | 1997-03-10 | 2002-10-24 | Ottawa Civic Loeb Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
DE69838294T2 (en) | 1997-05-20 | 2009-08-13 | Ottawa Health Research Institute, Ottawa | Process for the preparation of nucleic acid constructs |
PT1003850E (en) | 1997-06-06 | 2009-08-13 | Dynavax Tech Corp | Inhibitors of dna immunostimulatory sequence activity |
GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
IL121165A0 (en) | 1997-06-26 | 1997-11-20 | Yissum Res Dev Co | Pharmaceutical compositions containing carboxylic acids and derivatives thereof |
DE69815692T2 (en) | 1997-09-05 | 2004-04-29 | Glaxosmithkline Biologicals S.A. | OIL IN WATER EMULSIONS WITH SAPONINES |
ID26669A (en) | 1998-02-12 | 2001-01-25 | Immune Complex Corp | INTI HEPATITIS B PROTEINS MODIFIED BY STRATEGY AND ITS DECREASES |
US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
CA2323929C (en) | 1998-04-03 | 2004-03-09 | University Of Iowa Research Foundation | Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines |
JP2002511423A (en) | 1998-04-09 | 2002-04-16 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | vaccine |
TWI227241B (en) * | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
GB9817052D0 (en) | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
DE59806475D1 (en) | 1998-09-18 | 2003-01-09 | Pentapharm Ag Basel | Urokinase INHIBITORS |
WO2000021478A1 (en) | 1998-09-28 | 2000-04-20 | Hans Balle Aps | Lift, preferably for seats on wheelchairs |
US6203837B1 (en) | 1998-10-06 | 2001-03-20 | Xcafe' Llc | Coffee system |
CA2773698C (en) | 1998-10-16 | 2015-05-19 | Glaxosmithkline Biologicals S.A. | Adjuvant systems comprising an immunostimulant adsorbed to a metallic salt particle and vaccines thereof |
AU770802B2 (en) | 1998-10-21 | 2004-03-04 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Virus-like particles for the induction of autoantibodies |
WO2000026385A1 (en) | 1998-11-05 | 2000-05-11 | Powderject Vaccines, Inc. | Nucleic acid constructs for genetic immunization |
CN100534529C (en) | 1998-11-30 | 2009-09-02 | 希托斯生物技术股份公司 | Ordered molecular presentation of antigens, method of preparation and use |
EP1140157B1 (en) | 1998-12-21 | 2009-02-18 | MedImmune, Inc. | Streptococcus pneumoniae proteins and immunogenic fragments for vaccines |
TR200200633T2 (en) | 1998-12-23 | 2002-06-21 | Shire Biochem Inc. | New streptococcus antigens |
AUPP807399A0 (en) | 1999-01-08 | 1999-02-04 | Csl Limited | Improved immunogenic lhrh composition and methods relating thereto |
WO2000048630A1 (en) | 1999-02-17 | 2000-08-24 | Csl Limited | Immunogenic complexes and methods relating thereto |
HU228499B1 (en) | 1999-03-19 | 2013-03-28 | Smithkline Beecham Biolog | Streptococcus vaccine |
BR0009520A (en) | 1999-04-01 | 2002-06-11 | Esperion Therapeutics Inc | Compound, method to synthesize the same, composition, methods for treatment or prevention, in a patient, of cardiovascular disease, dyslipidemia, dyslipoproteinemia, glucose metabolism disorder, alzheimer's disease, syndrome x or metabolic syndrome, septicemia, thrombotic disorder, disorder associated with peroxisome proliferator-activated receptor, obesity, pancreatitis, hypertension, kidney disease, cancer, inflammation, impotence, to reduce the fat content of beef cattle, and to reduce the cholesterol content of poultry eggs |
CA2365914A1 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
GB9908533D0 (en) | 1999-04-14 | 1999-06-09 | Novartis Ag | Organic compounds |
PT1187629E (en) | 1999-04-19 | 2005-02-28 | Glaxosmithkline Biolog Sa | ADJUVANT COMPOSITION THAT UNDERSTANDS SAPONIN AND AN IMMUNOSTIMULATOR OLIGONUCLEOTIDE |
NO309798B1 (en) * | 1999-04-30 | 2001-04-02 | Targovax As | Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition |
CO5200837A1 (en) | 1999-09-24 | 2002-09-27 | Smithkline Beecham Corp | VACCINES |
PL355232A1 (en) | 1999-09-24 | 2004-04-05 | Smithkline Beecham Biologicals S.A. | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
EP1220684B2 (en) | 1999-09-27 | 2010-07-14 | Coley Pharmaceutical Group, Inc. | Methods related to immunostimulatory nucleic acid-induced interferon |
GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
EP1268530B1 (en) | 2000-04-07 | 2006-08-16 | University Of Leeds | Hepatitis b core antigen fusion proteins |
AU2001252458A1 (en) | 2000-05-05 | 2001-11-20 | Martin Bachmann | Molecular antigen arrays and vaccines |
NZ553554A (en) | 2000-06-20 | 2008-11-28 | Id Biomedical Corp | Streptococcus antigens |
ES2260235T3 (en) | 2000-06-22 | 2006-11-01 | Ucb Pharma Limited | MODIFICATION OF THE "CORE" ANTIGEN OF HEPATITIS B. |
EP1304947A1 (en) | 2000-07-15 | 2003-05-02 | Lighthouse Display International Limited | Shelf edge display fittings |
GB0121171D0 (en) * | 2001-08-31 | 2001-10-24 | Glaxosmithkline Biolog Sa | Vaccine |
AUPQ912000A0 (en) | 2000-07-31 | 2000-08-24 | Crown In The Right Of The Queensland Department Of Health, The | Improved virus like particles |
US20030138769A1 (en) | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
US7320793B2 (en) * | 2001-01-19 | 2008-01-22 | Cytos Biotechnology Ag | Molecular antigen array |
US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
CA2492823A1 (en) | 2001-09-14 | 2003-03-27 | Martin F. Bachmann | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
DE60234375D1 (en) * | 2001-09-14 | 2009-12-24 | Cytos Biotechnology Ag | PACKAGING IMMUNSTIMULATING CpG IN VIRUS LIKE PARTICLES: PREPARATION METHOD AND USE |
JP4671389B2 (en) | 2001-10-05 | 2011-04-13 | サイトス バイオテクノロジー アーゲー | Angiotensin peptide-carrier complex and use thereof |
US7262024B2 (en) | 2001-12-20 | 2007-08-28 | Id Biomedical Corporation | Streptococcus antigens |
AU2003213168A1 (en) | 2002-02-21 | 2003-12-19 | Apovia, Inc. | IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE |
GB0209878D0 (en) | 2002-04-30 | 2002-06-05 | Glaxosmithkline Biolog Sa | Vaccine |
MXPA05000277A (en) | 2002-07-17 | 2005-03-31 | Cytos Biotechnology Ag | Molecular antigen arrays using a virus like particle derived from the ap205 coat protein. |
GB0219524D0 (en) * | 2002-08-21 | 2002-10-02 | Queen Mary & Westfield College | Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor |
ATE546156T1 (en) | 2002-12-10 | 2012-03-15 | Sanofi Pasteur Biologics Co | STABILIZED IMMUNOGENIC CHIMERIC HBC PARTICLES |
DE602004010376T2 (en) | 2003-03-13 | 2008-10-23 | Glaxosmithkline Biologicals S.A. | PROCESS FOR CLEANING BACTERIAL CYTOLYSIN |
EP1471152A1 (en) | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations in the human PCSK9 gene associated to hypercholesterolemia |
JP2008506683A (en) | 2004-07-18 | 2008-03-06 | コーリー ファーマシューティカル グループ, リミテッド | Methods and compositions for inducing innate immune responses |
NZ553244A (en) | 2004-07-18 | 2009-10-30 | Csl Ltd | Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses |
GB0421083D0 (en) | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
EP1736538A1 (en) | 2005-06-21 | 2006-12-27 | Cytos Biotechnology AG | Process for the preparative purification of virus-like-particles (VLPs) |
ES2553284T5 (en) | 2006-02-15 | 2021-08-31 | Rechtsanwalt Thomas Beck | Compositions and Procedures for Oligonucleotide Formulations |
CA2652247C (en) * | 2006-05-08 | 2015-11-17 | Adaerata, Limited Partnership | Chimeric pcsk9 proteins, cells comprising same, and assays using same |
US7572618B2 (en) * | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
US20080166785A1 (en) | 2006-08-16 | 2008-07-10 | Monica Sala-Schaeffer | Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use |
US8263353B2 (en) * | 2007-03-27 | 2012-09-11 | Merck Sharp & Dohme Corp. | Method for detecting autoprocessed, secreted PCSK9 |
AR066042A1 (en) * | 2007-04-13 | 2009-07-22 | Novartis Ag | MOLECULES AND METHODS TO MODULATE PROTEIN CONVERTASA-SUBTILISIN / QUEXIN TYPE 9 (PCSK9) |
KR20100045445A (en) | 2007-06-26 | 2010-05-03 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
JOP20080381B1 (en) * | 2007-08-23 | 2023-03-28 | Amgen Inc | Antigen Binding Proteins to Proprotein Convertase subtillisin Kexin type 9 (pcsk9) |
US8598320B2 (en) * | 2007-10-26 | 2013-12-03 | Merck Sharp & Dohme Corp. | Anti-PCSK9 and methods for treating lipid and cholesterol disorders |
CA2710141A1 (en) * | 2007-12-20 | 2009-07-02 | Cytos Biotechnology Ag | Ngf conjugates and uses thereof |
AR070316A1 (en) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | PCSK9 ANTAGONISTS (SUBTILISINE-KEXINA TYPE 9 PROPROTEIN) |
AR070315A1 (en) * | 2008-02-07 | 2010-03-31 | Merck & Co Inc | ANTIBODIES 1B20 ANTAGONISTS OF PCSK9 |
TWI516501B (en) * | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Pcsk9 antagonists |
AT507604A1 (en) | 2008-11-19 | 2010-06-15 | Affiris Forschungs & Entwicklungs Gmbh | TREATMENT OF ATHEROSCLEROSIS |
US9501570B2 (en) | 2014-07-14 | 2016-11-22 | Verizon Patent And Licensing Inc. | Dynamic routing system |
US9719791B2 (en) | 2014-12-10 | 2017-08-01 | Mapquest, Inc. | Computerized systems and methods for providing travel information and/or content to users |
WO2017221077A2 (en) | 2016-06-23 | 2017-12-28 | Steam Cc Ltd. | Method and apparatus for printing on a drink |
US10114918B2 (en) | 2016-01-27 | 2018-10-30 | Arm Limited | Physical placement control for an integrated circuit based on state bounds file |
-
2010
- 2010-08-23 PE PE2016002242A patent/PE20161560A1/en not_active Application Discontinuation
- 2010-08-23 PE PE2012000286A patent/PE20121544A1/en active IP Right Grant
- 2010-08-23 NZ NZ620441A patent/NZ620441A/en not_active IP Right Cessation
- 2010-08-23 KR KR1020137034292A patent/KR101660578B1/en active IP Right Grant
- 2010-08-23 AU AU2010290931A patent/AU2010290931B2/en not_active Ceased
- 2010-08-23 CN CN201510017173.9A patent/CN104548089B/en not_active Expired - Fee Related
- 2010-08-23 TR TR2018/08222T patent/TR201808222T4/en unknown
- 2010-08-23 NZ NZ710626A patent/NZ710626A/en not_active IP Right Cessation
- 2010-08-23 HU HUE10754583A patent/HUE037416T2/en unknown
- 2010-08-23 CA CA2771770A patent/CA2771770A1/en not_active Abandoned
- 2010-08-23 DK DK10754583.2T patent/DK2473605T3/en active
- 2010-08-23 CA CA2846746A patent/CA2846746A1/en not_active Abandoned
- 2010-08-23 PT PT107545832T patent/PT2473605T/en unknown
- 2010-08-23 NZ NZ599059A patent/NZ599059A/en not_active IP Right Cessation
- 2010-08-23 ES ES10754583.2T patent/ES2670576T3/en active Active
- 2010-08-23 NO NO10754583A patent/NO2473605T3/no unknown
- 2010-08-23 EP EP20140198381 patent/EP2865752A1/en not_active Withdrawn
- 2010-08-23 MY MYPI2012000934A patent/MY163512A/en unknown
- 2010-08-23 RU RU2012107657/10A patent/RU2538162C2/en not_active IP Right Cessation
- 2010-08-23 EP EP18158216.4A patent/EP3358008A1/en not_active Withdrawn
- 2010-08-23 SG SG10201401515YA patent/SG10201401515YA/en unknown
- 2010-08-23 PL PL10754583T patent/PL2473605T3/en unknown
- 2010-08-23 PE PE2016002226A patent/PE20161551A1/en not_active Application Discontinuation
- 2010-08-23 SG SG10201401516XA patent/SG10201401516XA/en unknown
- 2010-08-23 SG SG2012010740A patent/SG178447A1/en unknown
- 2010-08-23 CN CN201080049440.6A patent/CN102612558B/en not_active Expired - Fee Related
- 2010-08-23 BR BR112012004807A patent/BR112012004807A2/en not_active Application Discontinuation
- 2010-08-23 SI SI201031682T patent/SI2473605T1/en unknown
- 2010-08-23 CN CN201510017534.XA patent/CN104587462B/en not_active Expired - Fee Related
- 2010-08-23 MX MX2012002639A patent/MX2012002639A/en active IP Right Grant
- 2010-08-23 KR KR1020127005678A patent/KR101512053B1/en not_active IP Right Cessation
- 2010-08-23 WO PCT/IB2010/053784 patent/WO2011027257A2/en active Application Filing
- 2010-08-23 JP JP2012527419A patent/JP2013503623A/en not_active Withdrawn
- 2010-08-23 KR KR1020137034291A patent/KR101660577B1/en active IP Right Grant
- 2010-08-23 EP EP10754583.2A patent/EP2473605B1/en not_active Not-in-force
- 2010-08-27 TW TW099128951A patent/TWI400085B/en not_active IP Right Cessation
- 2010-08-31 US US12/872,645 patent/US8889144B2/en not_active Expired - Fee Related
- 2010-09-01 AR ARP100103197A patent/AR078247A1/en not_active Application Discontinuation
- 2010-09-01 SA SA110310687A patent/SA110310687B1/en unknown
- 2010-09-01 SA SA114350179A patent/SA114350179B1/en unknown
- 2010-09-01 SA SA114350178A patent/SA114350178B1/en unknown
-
2012
- 2012-02-20 IL IL218229A patent/IL218229A/en not_active IP Right Cessation
- 2012-02-24 CO CO12033031A patent/CO6501190A2/en unknown
-
2013
- 2013-01-23 HK HK13101001.0A patent/HK1174056A1/en not_active IP Right Cessation
-
2014
- 2014-10-07 US US14/508,977 patent/US9481875B2/en not_active Expired - Fee Related
- 2014-10-29 RU RU2014143531A patent/RU2014143531A/en not_active Application Discontinuation
-
2015
- 2015-02-04 JP JP2015020387A patent/JP5859150B2/en not_active Expired - Fee Related
- 2015-09-11 HK HK15108893.4A patent/HK1208346A1/en not_active IP Right Cessation
- 2015-10-21 HK HK15110331.0A patent/HK1209619A1/en not_active IP Right Cessation
- 2015-12-15 JP JP2015244111A patent/JP2016106089A/en not_active Withdrawn
-
2016
- 2016-01-04 PH PH12016500004A patent/PH12016500004A1/en unknown
- 2016-01-06 PH PH12016500040A patent/PH12016500040A1/en unknown
- 2016-09-15 US US15/266,812 patent/US9987341B2/en not_active Expired - Fee Related
- 2016-10-06 JP JP2016198088A patent/JP2017039748A/en active Pending
- 2016-12-07 AR ARP160103766A patent/AR107020A2/en unknown
-
2017
- 2017-09-19 IL IL254600A patent/IL254600A0/en unknown
- 2017-10-06 JP JP2017195839A patent/JP2018039821A/en active Pending
-
2018
- 2018-04-19 US US15/957,835 patent/US20180318407A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL254600A0 (en) | Pcsk9 vaccine | |
IL217008A0 (en) | Vaccine | |
GB0905570D0 (en) | Combined vaccines | |
IL211233A0 (en) | Vaccine | |
HRP20151124T1 (en) | Vaccine | |
EP2408473A4 (en) | Vaccination methods | |
GB0822001D0 (en) | Vaccine | |
GB201006165D0 (en) | Vaccine | |
GB0810710D0 (en) | Vaccine | |
IL208652A0 (en) | Vaccine | |
GB0816284D0 (en) | Vaccine | |
GB0907935D0 (en) | Vaccines | |
IL216102A0 (en) | Combined measles-malaria vaccine | |
GB0816447D0 (en) | Vaccine | |
GB201000522D0 (en) | Vaccine | |
IL217194A0 (en) | Vaccine | |
GB0914545D0 (en) | Vaccine | |
ZA201107971B (en) | Combined measles-malaria vaccine | |
GB0909146D0 (en) | Vaccines | |
GB0909147D0 (en) | Vaccines | |
GB0909145D0 (en) | Vaccines | |
GB0909144D0 (en) | Vaccines | |
GB0810215D0 (en) | Vaccine | |
GB0810914D0 (en) | Vaccine | |
GB0809781D0 (en) | Vaccine |